iCAD, a company providing advanced image analysis and radiation therapy for early detection and treatment of cancer, will present advanced computer-aided detection (CAD) solutions aimed at primary identification of breast and colon cancers, during the 100th Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Nov. 30 – Dec. 5.
During the meeting there will be oral presentations and scientific posters to discuss the potential applications of iCAD innovative technologies for cancer imaging and detection, analysis of breast density and morphological characterization of tumors. These include 2D mammographies, tomosynthesis, and Computed Tomography Colonography (CTC) CAD.
“We are pleased to showcase our latest Cancer Detection technologies at the 100th RSNA meeting. Cancer Detection technologies have been proven to help radiologists identify cancer earlier, when there may be more treatment options available,” Ken Ferry, President and CEO of iCAD said in a press release. “With medical imaging’s rapid evolution, iCAD continues to build its CAD offerings to ensure that radiologists have access to the most innovative solutions for optimal patient care.”
iCAD will present the PowerLook Advanced Mammography Platform (AMP), which is designed to allow radiologists the capacity to customize their platform solution. This platform is equipped with artificial intelligence and pattern recognition technology that can identify potential cancers, and mark doubtful areas without concealing the underlying image.
The company will also present its innovative VeraLook CTC, the first FDA-cleared CAD technology for CTC.
iCAD’s presentations will have a major focus on the role of volumetric density in adjunctive imaging for women with dense breasts. Additionally, iCAD will also present different products from its line of technology platforms, including iCAD’s Xoft® cervical brachytherapy for gynecological cancers and MRI imaging for pediatric brain tumors.
To emphasize the company’s pledge towards early cancer detection, iCAD will also lead a social media campaign to support the Imerman Angels, a Chicago-based organization that gives support to patients dealing with cancer along with survivors and caregivers.
Meeting participants can share the reasons that drive them to “never stop looking” in social media platforms and use the hashtag #MySight in their posts.